Should I buy Tandem Diabetes Care (TNDM) stock or is it too late?
No reliable analyst is bullish on this stock right now. A “reliable” analyst is a firm that, on this sector, hits more than 55% of its targets and beats its sector. None of them sees upside here — which is exactly why this stock is in no JPI selection.
Firm-by-firm track record on Tandem Diabetes Care
| Firm | % right | Gain vs sector | Calls | Aims for |
|---|---|---|---|---|
| Piper Sandler | 30 % | +31.5 % | 10 | $33 +54% |
| Canaccord Genuity | 40 % | -0.8 % | 5 | $35 +64% |
| Barclays | 50 % | -3.5 % | 8 | $55 +157% |
| Citigroup | 38 % | -11.6 % | 8 | $21 -2% |
| Wells Fargo | 25 % | -36.4 % | 8 | $27 +26% |
| Deutsche Bank | 0 % | -45.3 % | 5 | $16 -28% |
| Stifel | 0 % | -45.4 % | 7 | $22 +3% |
| Raymond James | 50 % | -14.3 % | 12 | — |
✅ Reasons to believe
- Median price target $26, i.e. +19% from the current price ($21).
- The most reliable firm on TNDM, UBS (100% hit rate, 3 scored calls), targets $22 (call made on February 20, 2026, maturing on February 20, 2027) (+3%) in its most recent call.
⚠️ Reasons to hesitate
- The consensus is not unanimous: of 14 ratings, 7 are neutral.
- A 12-month target is not a guaranteed path: the price can fall in the meantime.
- No dividend: your return depends only on price appreciation.
The analyst consensus on TNDM
Median target $26 (+19%) · 14 ratings · Buy consensus
⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.
Frequently asked questions
Should you invest in Tandem Diabetes Care now?
We won't decide for you. The facts: 50% of analysts rate it a buy, median target $26 (+19%), and UBS (most reliable on TNDM, 100%) targets $22. Weigh that against valuation. This is not personalized advice.
Is it too late to invest in Tandem Diabetes Care?
Not according to analysts: the median target ($26) is still +19% above the current price ($21) (most reliable on TNDM: UBS, 100%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.
Is Tandem Diabetes Care still worth investing in?
It depends on the gap between the price ($21) and its estimated value: analysts target $26 on median (+19%), with 50% buys (most reliable on TNDM: UBS, 100%). Cross-check with their real reliability on TNDM and the cautions above. Information, not advice.
What's the main risk in buying TNDM?
The consensus is not unanimous: of 14 ratings, 7 are neutral.
→ Go deeper: the full Tandem Diabetes Care profile (consensus, analyst reliability, price target, performance).